Candel burns bright as phase 3 prostate cancer win sends stock up 200%
A phase 3 prostate cancer trial of Candel’s oncolytic virus has met its primary endpoint, sending the stock up more than 200%. The phase 3 hit was however offset by the failure of a midphase study buried deeper within its trial win release.
Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...
After announcing he was cancer-free over the summer, Hall of Fame second baseman Ryne Sandberg says disease is back and has ...
The new blood-based test — called AR-ctDETECT — is designed to detect and analyze small fragments of tumor-derived DNA in the ...
Amid Golden Bachelor Gerry Turner’s diagnosis with an incurable type of cancer, his ex-wife Theresa Nist shared her heartfelt ...
Montell Jordan is advocating for prostate cancer awareness and emphasizing the importance of early detection, particularly ...
Investigators assessed the oncologic benefit of salvage radiation therapy versus observation for men with biochemical recurrence after radical prostatectomy.
Former Chicago Cubs player Ryne Sandberg recently took to social media to share a devastating update regarding his health ...
A breakthrough study has identified the genetic risk factors that contribute to increased prostate cancer in African men. The ...
Treatment with five-fraction SBRT could be effective versus traditional radiation in certain patients with low- or ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback